A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II/III study to
evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in
patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed
to EGFR-TKI treatment.